Titan Pharmaceuticals, Inc.  

(Public, NASDAQ:TTNP)   Watch this stock  
Find more results for ttnp
6.86
-0.21 (-2.97%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.61 - 8.74
52 week 2.57 - 10.00
Open 8.51
Vol / Avg. 9.43M/739,076.00
Mkt cap 133.69M
P/E     -
Div/yield     -
EPS -0.41
Shares 20.08M
Beta 1.93
Inst. own 3%
Aug 11, 2016
Q2 2016 Titan Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
May 10, 2016
Q1 2016 Titan Pharmaceuticals Inc Earnings Call
May 10, 2016
Q1 2016 Titan Pharmaceuticals Inc Earnings Release
Mar 15, 2016
Q4 2015 Titan Pharmaceuticals Inc Earnings Call
Mar 15, 2016
Q4 2015 Titan Pharmaceuticals Inc Earnings Release
Mar 14, 2016
Titan Pharmaceuticals Inc at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -674.99%
Operating margin - -404.49%
EBITD margin - -383.06%
Return on average assets -58.57% -66.08%
Return on average equity -118.79% -144.59%
Employees 13 -
CDP Score - -

Address

400 Oyster Point Blvd Ste 505
SOUTH SAN FRANCISCO, CA 94080-1958
United States - Map
+1-415-2444990 (Phone)
+1-650-2444956 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.

Officers and directors

Marc Rubin M.D. Executive Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Sunil Ramraje Bhonsle President, Director
Age: 65
Bio & Compensation  - Reuters
Joseph A. Akers Independent Director
Age: 69
Bio & Compensation  - Reuters
Victor J. Bauer Ph.D. Independent Director
Age: 79
Bio & Compensation  - Reuters
Eurelio M. Cavalier Independent Director
Age: 82
Bio & Compensation  - Reuters
M. David David MacFarlane Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
James R. McNab Jr. Independent Director
Age: 71
Bio & Compensation  - Reuters